Key facts
- It has raised $68.7M; the latest was Seed Round ($27.7M) in Mar 2026.
- Notable investors include HSG (Hong Kong), 5Y Capital, YuanBio Venture Capital, Co-Win Ventures, Hony Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Aikelian Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Aikelian Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aikelian Biotechnology
Provider of biotechnology research and development services catering to the life sciences and pharmaceutical sectors. The company offers cell line development, protein expression, antibody discovery, assay development, bioanalytical testing, molecular biology services, preclinical research support, and laboratory testing, thereby enabling accelerated drug development, improved research efficiency, and reliable experimental outcomes.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2025
- Website
- excalipoint.com/
- Ownership
- Privately Held (backing)
Aikelian Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aikelian Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aikelian Biotechnology in its N-PORT filings yet. We sweep new filings monthly.